Industry Experts blogging about Dry Eye Disease
Tokyo, Japan, November 9, 2010 In a press release, Otsuka Pharmaceutical Co., Ltd. today announced it has applied for regulatory approval in Japan to manufacture and market Mucosta® (rebamipide) ophthalmic suspension for treatment of dry eye. By its novel mechanism of action to promote the production of mucin in the ocular … [Read more...]
In my initial work with the TearLab, I have been very impressed and encouraged by the ease of use and consistent findings. I expect that this technology will help me provide better care for my patients, particularly those with ocular surface disease. We are currently conducting a study to determine the relationship between … [Read more...]
Laboratory vs Physician Fee Schedule A new CPT Code has recently been issued for the TearLab osmolarity test used for the diagnosis and management of dry eye disease: “83861 Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity”, and will be effective January 1, 2011. This is an … [Read more...]
